A
Akanda Corp
NASDAQ:AKAN
Akanda Corp
NASDAQ:AKAN
Price:
3.13
USD
-0.95%
Market Cap:
$6.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
A
|
Akanda Corp
NASDAQ:AKAN
|
UK |
|
Offcn Education Technology Co Ltd
SZSE:002607
|
CN |
|
Swiss Water Decaffeinated Coffee Inc
TSX:SWP
|
CA |
|
Taichung Commercial Bank Co Ltd
TWSE:2812
|
TW |
|
Nomura Research Institute Ltd
TSE:4307
|
JP |
|
P
|
Platige Image SA
WSE:PLI
|
PL |
|
Kymera Therapeutics Inc
NASDAQ:KYMR
|
US |
|
S
|
SK Discovery Co Ltd
KRX:006120
|
KR |
|
Marvel Gold Ltd
ASX:MVL
|
AU |
|
A
|
Alony Hetz Properties and Investments Ltd
TASE:ALHE
|
IL |
|
Cloud Factory Technology Holdings Ltd
HKEX:2512
|
CN |
|
IQE PLC
LSE:IQE
|
UK |
|
Tesec Corp
TSE:6337
|
JP |
|
O
|
Oriental Interest Bhd
KLSE:OIB
|
MY |
|
V
|
Vunani Ltd
JSE:VUN
|
ZA |
|
Renaissance United Ltd
SGX:I11
|
SG |
Multiples-Based Value
The Multiples-Based Value for Akanda Corp (AKAN) under the Base Case is hidden USD. Compared with the current market price of 3.13 USD, the stock appears hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
AKAN Multiples-Based Value
LOCKED
Multiples Across Competitors
AKAN Competitors Multiples
Akanda Corp Competitors
Akanda Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
A
|
Akanda Corp
NASDAQ:AKAN
|
6.3m USD | 7.5 | -1.5 | -0.1 | -0.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
871.6B USD | 13.4 | 42.3 | 28.6 | 30.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.1B USD | 6.1 | 21.5 | 14.9 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.4B GBP | 5.2 | 29.9 | 16.6 | 23.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296.9B USD | 4.5 | 16.1 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.8B CHF | 5.1 | 20.6 | 12.7 | 16.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
89.3B GBP | 2.7 | 15.4 | 8.4 | 10.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
